Proton pump inhibitors and risk for recurrent clostridium difficile infection

Archives of Internal Medicine

Volumn 170, Issue 9, 2010, Pages 772-778

  Linsky, Amy ^a   Gupta, Kalpana ^b,c   Lawler, Elizabeth V ^b,c   Fonda, Jennifer R ^b   Hermos, John A ^a,b,c  

^a BOSTON MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT INFECTION;

AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEW ENGLAND; PROTON PUMP INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; VETERANS;

EID: 77952196958     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.73     Document Type: Article

References (30)

1. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol. 2009; 104(2)(suppl 2):S27-S32.
2. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98(1): 51-58.
3. Brummer RJ, Stockbrugger RW. Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer. Dig Dis Sci. 1996;41(10):2048-2054.
4. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104(2)(suppl 2):S10-S16.
5. García Rodríguez LA, Ruigómez A, Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5(12): 1418-1423. (Pubitemid 350181606)
6. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391-398.
7. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120-2128.
8. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171(1):33-38. (Pubitemid 38925116)
9. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989-2995. (Pubitemid 41817660)
10. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308-2313.
11. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243-245. (Pubitemid 38002001)
12. Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium difficile colitis: factors influencing treatment failure and relapse: a prospective evaluation. Am J Gastroenterol. 1998;93(10):1873-1876. (Pubitemid 29071697)
13. Tal S, Gurevich A, Guller V, Gurevich I, Berger D, Levi S. Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly. Scand J Infect Dis. 2002;34(8):594-597. (Pubitemid 35012343)
14. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70(4):298-304.
15. Maroo S, Lamont JT. Recurrent clostridium difficile. Gastroenterology. 2006;130 (4):1311-1316.
16. Kelly CP, LaMont JT. Clostridium difficile: more difficult than ever. N Engl J Med. 2008;359(18):1932-1940.
17. Loo VG, Libman MD, Miller MA, et al. Clostridium difficile: a formidable foe. CMAJ. 2004;171(1):47-48.
18. Dubberke ER, Reske KA, Olsen MA, et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. Arch Intern Med. 2007;167(10):1092-1097. (Pubitemid 46835798)
19. Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006;175(7):745-748. (Pubitemid 44520987)
20. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ. 2008; 179(8):767-772.
21. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a populationbased study. Clin Infect Dis. 2006;43(10):1272-1276.
22. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62(2):388-396.
23. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189-193.
24. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of protonpump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. 2007;64(22):2359-2363.
25. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983;2(8358):1043-1046.
26. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302-307.
27. Lai KK, Melvin ZS, Menard MJ, Kotilainen HR, Baker S. Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol. 1997;18(9):628-632.
28. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol. 2008;29(1):44-50.
29. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320(4):204-210.
30. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998; 40(1):1-15.